Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced it will release fourth quarter and full year 2019 financial results after the market closes on Monday, March 2nd, 2020. The Company will host a conference call that day at 5:30 pm ET to discuss the results and provide a general business update.

Q1 2020 Precigen Inc Earnings Call

The Germantown company has new leadership, a new name and deals to sell off assets in exchange for millions.

Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced the closing of its previously announced sale of a number of its bioengineering assets and the related sale of $35 million of its common stock to an affiliate of Third Security LLC. Additionally, effective February 1, 2020, the Company has changed its name to Precigen, Inc. from Intrexon Corporation and its Nasdaq stock symbol to PGEN from XON. The new Precigen enters 2020 with a promising portfolio of investigational gene and cell therapies, derived from the Company's transformative therapeutic platforms, including UltraCAR-T™, AdenoVerse™ cytokine therapies, multifunctional therapeutics and off-the-shelf AdenoVerse™ immunotherapies, as well as innovative approaches from our subsidiaries ActoBio Therapeutics, Exemplar Genetics, and Triple-Gene.

Is Intrexon Corp (NASDAQ:XON) a good investment right now? We check hedge fund and billionaire investor sentiment before delving into hours of research. Hedge funds spend millions of dollars on Ivy League graduates, unconventional data sources, expert networks, and get tips from investment bankers and industry insiders. Sure they sometimes fail miserably, but their consensus […]

Darling Ingredients Inc. (NYSE: DAR), today announced that it has acquired the 50% joint venture interest of EnviroFlight, LLC owned by Intrexon Corporation (NASDAQ: XON), thereby increasing its ownership interest in EnviroFlight to 100%. EnviroFlight, LLC is a leading developer of proprietary technologies which enable the rearing of non-pathogenic black soldier fly (BSF) larvae in a scalable manner. This innovative and responsible approach has considerable potential within the sizable global animal feed industry as it will provide an environmentally-friendly, toxin-free, sustainable source of high-value nutrients. Enviroflight opened the first commercial BSF facility in Maysville, Kentucky in late 2018. Phase 1 of this production facility currently has the capacity to produce 900 tons of dried BSF larvae on an annual basis.

Precigen, Inc., a biopharmaceutical company specializing in the development of innovative gene and cellular therapies to improve the lives of patients, today announced that the US Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to PRGN-3006, a first-in-class investigational therapy using Precigen's non-viral UltraCAR-T™ therapeutic platform for patients with relapsed or refractory acute myeloid leukemia (AML) (clinical trial identifier: NCT03927261). Precigen announced in Q3 2019 that it had completed enrollment for the first cohort of this clinical trial and expects an initial data readout in the second half of 2020.

Just four days after Intrexon Corp. (NASDAQ: XON) made public plans to rebrand as Precigen, its subsidiary by the same name has secured a coveted regulatory designation for its blood cancer treatment. Germantown’s Precigen Inc. has earned orphan drug status from the Food and Drug Administration for its therapy for relapsed or refractory acute myeloid leukemia, a form of cancer in the blood and bone marrow, in cases that have either come back or failed to respond to past treatment. The company expects data from phase 1 clinical trials in the second half of this year.

Triple-Gene LLC, a clinical stage cardiovascular gene therapy company, today announced that Thomas D. Reed, PhD, Co-Founder, will present at the Biotech Showcase on January 15th, 2020 at 11:30AM PT at the Hilton San Francisco Union Square.

Investors need to pay close attention to Intrexon (XON) stock based on the movements in the options market lately.

- Tightened focus on healthcare and on track to meet yearend transactional and cash goals - - Quarterly GAAP revenues of $23.0 million and net loss attributable to Intrexon of $53.6 million including non-cash ...

Intrexon (XON) posts a narrower-than-expected loss and misses sales estimates in the third quarter of 2019.

GERMANTOWN, Md. , Nov. 18, 2019 /PRNewswire/ --  Triple-Gene LLC , a clinical stage cardiovascular gene therapy company and majority owned subsidiary of Intrexon Corporation (NASDAQ: XON), yesterday presented ...

Precigen (PGEN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Intrexon Corporation (NASDAQ: XON), a leader in the engineering and industrialization of biology to improve the quality of life and health of the planet, announced today that it will refocus the company on healthcare, change its name to Precigen, Inc. and, effective immediately, has appointed Helen Sabzevari, PhD, as President and CEO. The new Precigen will encompass Intrexon's wholly-owned healthcare subsidiaries Precigen, ActoBio Therapeutics, Exemplar Genetics, and its majority ownership interest in Triple-Gene, as well as equity and royalty interests in therapeutics and therapeutic platforms from companies not controlled by Intrexon. Randal J. Kirk has been appointed Executive Chairman. Additionally, Intrexon has executed binding agreements to sell its smaller non-healthcare businesses for $65.2M plus certain contingent payment rights and entered into an agreement to sell $35M of its common stock. The proceeds from these transactions, combined with the company's cash and short-term investments on hand at December 31, 2019, approximates $175 million thus attaining Intrexon's year-end objective.

Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced its fourth quarter financial results for 2019.

Biotech stocks went about a consolidation move last week, although a few swung wildly in either direction in reaction to some catalytic events. Aslan  (NASDAQ: ASLN ) tumbled  after its late-stage biliary ...

The FDA grants orphan drug designation to PRGN-3006, a rare cancer candidate in Precigen's portfolio, which is a subsidiary of Intrexon (XON).

In 2009 RJ Kirk was appointed CEO of Intrexon Corporation (NASDAQ:XON). This report will, first, examine the CEO...

Q4 2019 Precigen Inc Earnings Call